Literature DB >> 8774539

The D2 dopamine receptor gene as a determinant of reward deficiency syndrome.

K Blum1, P J Sheridan, R C Wood, E R Braverman, T J Chen, J G Cull, D E Comings.   

Abstract

The dopaminergic system, and in particular the dopamine D2 receptor, has been profoundly implicated in reward mechanisms in the brain. Dysfunction of the D2 dopamine receptors leads to aberrant substance seeking behaviour (alcohol, drug, tobacco, and food) and other related behaviours (pathological gambling, Tourette's syndrome, and attention deficit hyperactivity disorder). We propose that variants of the D2 dopamine receptor gene are important common genetic determinants of the 'reward deficiency syndrome'.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774539      PMCID: PMC1295855          DOI: 10.1177/014107689608900711

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  47 in total

1.  The D2 dopamine receptor and Tourette's syndrome.

Authors:  E J Devor
Journal:  JAMA       Date:  1992-02-05       Impact factor: 56.272

2.  Alcoholism and alleles of the human D2 dopamine receptor locus. Studies of association and linkage.

Authors:  A Parsian; R D Todd; E J Devor; K L O'Malley; B K Suarez; T Reich; C R Cloninger
Journal:  Arch Gen Psychiatry       Date:  1991-07

3.  Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism.

Authors:  E P Noble; K Blum; T Ritchie; A Montgomery; P J Sheridan
Journal:  Arch Gen Psychiatry       Date:  1991-07

4.  Haplotyping by double PCR amplification of specific alleles.

Authors:  G Sarkar; S S Sommer
Journal:  Biotechniques       Date:  1991-04       Impact factor: 1.993

5.  Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism.

Authors:  A M Bolos; M Dean; S Lucas-Derse; M Ramsburg; G L Brown; D Goldman
Journal:  JAMA       Date:  1990-12-26       Impact factor: 56.272

6.  A new TaqI RFLP within intron 2 of human dopamine D2 receptor gene (DRD2).

Authors:  A Parsian; L Fisher; K L O'Malley; R D Todd
Journal:  Nucleic Acids Res       Date:  1991-12-25       Impact factor: 16.971

7.  Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene.

Authors:  X Y Hauge; D K Grandy; J H Eubanks; G A Evans; O Civelli; M Litt
Journal:  Genomics       Date:  1991-07       Impact factor: 5.736

8.  The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking.

Authors:  D E Comings; L Ferry; S Bradshaw-Robinson; R Burchette; C Chiu; D Muhleman
Journal:  Pharmacogenetics       Date:  1996-02

9.  The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders.

Authors:  D E Comings; B G Comings; D Muhleman; G Dietz; B Shahbahrami; D Tast; E Knell; P Kocsis; R Baumgarten; B W Kovacs
Journal:  JAMA       Date:  1991-10-02       Impact factor: 56.272

10.  No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism.

Authors:  J Gelernter; S O'Malley; N Risch; H R Kranzler; J Krystal; K Merikangas; J L Kennedy; K K Kidd
Journal:  JAMA       Date:  1991-10-02       Impact factor: 56.272

View more
  142 in total

Review 1.  Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms.

Authors:  Kenneth Blum; Tonia Werner; Stefanie Carnes; Patrick Carnes; Abdalla Bowirrat; John Giordano; Marlene Oscar-Berman; Mark Gold
Journal:  J Psychoactive Drugs       Date:  2012 Jan-Mar

Review 2.  A review of smoking cessation interventions.

Authors:  Ashish Maseeh; Gagandeep Kwatra
Journal:  MedGenMed       Date:  2005-06-07

3.  Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)?

Authors:  Kenneth Blum; Marlene Oscar-Berman; William Jacobs; Thomas McLaughlin; Mark S Gold
Journal:  J Addict Res Ther       Date:  2014

4.  Behavioral economics of food reinforcement and the effects of prefeeding, extinction, and eticlopride in dopamine D2 receptor mutant mice.

Authors:  Paul L Soto; David K Grandy; Steven R Hursh; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2011-02-02       Impact factor: 4.530

Review 5.  Towards conceptualizing a neural systems-based anatomy of attention-deficit/hyperactivity disorder.

Authors:  Nikos Makris; Joseph Biederman; Michael C Monuteaux; Larry J Seidman
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

6.  Have We Hatched the Addiction Egg: Reward Deficiency Syndrome Solution System™

Authors:  Bw Downs; M Oscar-Berman; Rl Waite; Ma Madigan; J Giordano; T Beley; S Jones; T Simpatico; M Hauser; J Borsten; F Marcelo; Er Braverman; R Lohmann; K Dushaj; M Helman; D Barh; St Schoenthaler; D Han; K Blum
Journal:  J Genet Syndr Gene Ther       Date:  2013-06-03

Review 7.  Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy.

Authors:  Alexander M Lopez; Daniel Weintraub; Daniel O Claassen
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

8.  Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD).

Authors:  Kenneth Blum; Margaret A Madigan; Lyle Fried; Eric R Braverman; John Giordano; Rajendra D Badgaiyan
Journal:  Glob J Addict Rehabil Med       Date:  2017-02-23

Review 9.  Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation.

Authors:  Kenneth Blum; Marcelo Febo; David E Smith; A Kenison Roy; Zsolt Demetrovics; Frans J Cronjé; John Femino; Gozde Agan; James L Fratantonio; Subhash C Pandey; Rajendra D Badgaiyan; Mark S Gold
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04-28       Impact factor: 2.576

Review 10.  Emerging association between addictive gaming and attention-deficit/hyperactivity disorder.

Authors:  Aviv Weinstein; Abraham Weizman
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.